Our clinical programs investigate individualized treatments across a variety of malignancies
Our proprietary technologies have the capability to unlock the potential of personalized T-cell therapy for the treatment of cancer, as well as identify new targets in a number of other diseases.
We’re currently advancing the following clinical development programs:
TCX – 101 Pipeline Platform
α-HA-1*
Phase
Indication:
alloSCT (AML, ALL, MDS)
Discovery
PRE
1
2
Undisclosed
Phase
Indication:
alloSCT
Discovery
PRE
1
2
*HA-1: minor histocompatibility antigen 1; IND to be filed 1H2023
TCX – 201 Pipeline Platform / Neoantigen Programs
Individualized* - to be selected
Phase
Indication:
Solid Tumor
Discovery
PRE
1
2
Shared - to be selected
Phase
Indication:
Solid Tumor
Discovery
PRE
1
2
*Our individualized, preclinical Virtual Patient Program is ongoing and has targeted the following tumor types: Head & Neck, NSCLC, melanoma, renal cell carcinoma, and bladder.
Contact us to hear more about our clinical programs and technology.
